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Summary
BACKGROUND: Travel activity and travel-related risks
of patients after allogeneic haematopoietic stem cell trans-
plantation (allo-HSCT) remain largely unknown. The aim
of our study was to examine travel activity after allo-HSCT
including travel behaviour and travel patterns.
METHODS: We analysed travel characteristics of allo-
HSCT recipients by using a retrospective cross-sectional
survey. Allo-HSCT patients were asked to complete a ques-
tionnaire during their annual health visits from 2010 to
2012.
RESULTS: Overall, 118/153 (77%) participating patients
reported travel activity for a total of 201 travelling epis-
odes. Travellers versus non-travellers were receiving im-
munosuppressive treatment in 35.6% versus 65.7% (p =
0.002), and had graft-versus-host-disease (GvHD) in
52.5% versus 62.9% (p = 0.17). In a multivariate analysis,
the time between the transplantation and the survey was
the only factor associated with travel activity (p <0.0001)
and taking pretravel advice (p <0.0001). In 34.8% of travel
episodes pretravel advice was sought. Patients with pre-
travel advice reported travel-related symptoms more fre-
quently. Minor respiratory (27/201) and gastrointestinal
(23/201) symptoms were most frequently indicated. Four
percent (8/201) of the patients were hospitalised while trav-
elling.
CONCLUSION: We conclude that travelling after allo-
HSCT is frequent and linked to the time since transplanta-
tion. We could not define specific risks for any destination.
Nevertheless, pretravel advice and preparation are highly
recommended for immunosuppressed patients.
Key words: Allogeneic haematpoietic stem cell
transplantation (allo-HSCT); travel; complications;
destination; pretravel advice; risk factors
Introduction
Travelling is a challenge for immunosuppressed patients
owing to the complex medical conditions and an increased
risk of travel-associated infections. Most studies including
immunosuppressed travellers have focussed on patients
with solid organ transplants (SOTs), HIV infection or vari-
ous malignancies [1–4]. Type and severity of immunosup-
pression are highly diverse among these high-risk popula-
tions [5, 6].
In 2010, more than 12,000 allogeneic haematopoietic stem
cell transplantations (allo-HSCT) were performed in
Europe [7]. The continuous increase in survivors after allo-
HSCT will likely correlate with the number of high-risk
travellers in the near future. After allo-HSCT, immunosup-
pression is often prolonged, complex and associated with
an increased risk of infectious diseases [8, 9]. A profound
knowledge regarding travel behaviour is important in order
to provide the best recommendations for safe travel.
To the best of our knowledge, to date no guidelines re-
garding the time and specific conditions for travelling after
allo-HSCT have been published. Despite immunosuppres-
sion, safety during travel is crucial [10, 11]. For SOT re-
cipients travel to high-infection-risk destinations (Africa,
Asia, Middle and South America) should be postponed for
at least 1 year post-transplant according to the current re-
commendations of the Centres for Disease Control and Pre-
vention (CDC) [12]. Travel advice may depend on vari-
ous factors such as the degree of immunosuppression or
the travel destination. Immunosuppression after allo-HSCT
is variable and depends on induction treatment, type of
transplantation and manipulation of the transplant, status of
immune reconstitution, graft-versus-host-disease (GvHD),
and immunosuppressive treatments. The CDC considers
the presence of active GvHD, the need of on-going immun-
osuppressive treatment and a post-transplant time less than
2 years as conditions of severe immunosuppression [12].
After allo-HSCT, up to 50% of patients are affected by
chronic GvHD [13, 14]. In addition to the requirement for
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prolonged intensive immunosuppressive treatment, allo-
HSCT recipients with chronic GvHD are regarded as func-
tionally asplenic [15]. These factors significantly increase
the risk for infections and associated complications [16,
17].
Most studies of immune competent and compromised trav-
ellers focused on tropical and subtropical areas [3]. Never-
theless, in European countries also infectious diseases may
be challenging as a result of an increase of multidrug-resist-
ant Gram-negative bacteria such as in Escherichia coli and
Klebsiella pneumonia, with a perceptible north-to-south
gradient, reaching up to 50% of clinical isolates in popular
travel destinations such as Greece and Italy [18, 19].
Pretravel advice should help to identify specific risks and
potential travel-related problems. Among SOT patients
fewer than 50% seek pretravel advice [2, 3, 20]. These
patients primarily ask general practitioners or transplant
physicians for pretravel advice – and not infectious dis-
eases or travel medicine specialists. However, a study
among Swiss general practitioners showed that they often
do not feel up to the mark to counsel immunosuppressed
patients for before travelling [21]. Vaccination is a key top-
ic in pretravel advice and an important preventive strategy
to reduce the burden of infectious diseases. Live vaccines
are generally considered to be contraindicated in immun-
osuppressed hosts, including allo-HSCT patients [22]. In
addition, the vaccine-induced immune responses are often
poor.
Antibiotics for self-treatment by immunocompromised pa-
tients should be based on detailed knowledge of the en-
demic resistance patterns at a particular travel destination.
Therefore, instructions concerning risk behaviour, medic-
ation and necessary prophylaxis, preferably given by the
treating physician, are even more important [1, 20, 21].
The aim of our study was to identify travel patterns and
behaviours in patients after allo-HSCT. Our rationale was
that a broader understanding of travel behaviour in allo-
HSCT patients might help to improve pretravel advice for
this complex subset of high-risk travellers.
Methods
Figure 1
Distribution of reported travel destinations. In total 201 travel
episodes were reported.
Study design and participants
We performed a retrospective cross-sectional observational
study of travel behaviour in patients older than 18 years
after allo-HSCT. Between September 2010 and September
2012 patients attending a routine annual visit at the haemat-
ological outpatient clinic of the University Hospital Basel,
Switzerland, were asked to complete a questionnaire re-
garding travelling in the previous year. The questionnaire
was filled in at the outpatient clinic without any help of a
healthcare worker or study nurse. Information about med-
ication, remission state, grading of GvHD, underlying
haematological disease, and time since transplantation
were completed from the medical record. Patients with
missing baseline information or who answered the ques-
tionnaire incorrectly were excluded. All patients provided
a written informed consent statement. The study was ap-
proved through the local ethics committee (Ethikkommit-
tee beider Basel, EKBB, approved 2010, www.eknz.ch).
Questionnaire
The questionnaires included factors of the following four
categories:
I demographics, clinical information including time
since transplantation, and immunosuppressive drugs;
II general travel information including travel activity, de-
tails on travel destination, overall duration, purpose,
travel companions, and accommodation;
III pretravel medical advice;
IV during and after travel ‒ risk behaviour, symptoms and
medical advice.
The questionnaire was developed in collaboration with ex-
perts in haematology and infectious diseases at the
University Hospital Basel (Switzerland) and in travel medi-
cine at the Swiss Tropical and Public Health Institute
(Switzerland).
Definitions
Travel episodes were defined as journeys for 7 days or
more to any country outside of Switzerland within the
previous year. Multiple travel episodes per questionnaire
were possible. Reported countries were grouped into five
regions: Europe, Africa, Asia, North America, and Latin
America.
Based on guidelines of the CDC [12], we defined active
GvHD, concurrent immunosuppressive drugs or transplant-
ation within the previous 2 years as evidence of active im-
munosuppression.
Risk behaviour while travelling consisted of unprotected
sex, receiving tattoos or piercings, bathing in stagnant wa-
ter, close animal contact, receiving blood transfusions, and
risky eating habits (raw meat or fish, and ice cubes).
Health issues were divided into six groups: respiratory
(cough, cold, phlegm, sore throat), gastrointestinal (abdom-
inal cramps, diarrhoea), musculoskeletal (arthralgia,
rheumatic pains), urinary tract infections, dermatological
(skin rashes) and fever.
A personal visit to a healthcare provider (e.g. haematolo-
gist, general practitioner, travel medicine specialist) was
considered as pre- or post-travel advice.
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Statistical analysis
Primarily descriptive statistics was used for travel destin-
ations. Basic sociodemographic characteristics, type and
severity of immunosuppression, the presence of GvHD,
and time after allo-HSCT were compared between travel-
lers and non-travellers using the chi-square test for categor-
ical variables and the Mann-Whitney for continuous vari-
ables. A multivariate logistic regression model was used
to explore predictors of travelling by patients after allo-
HSCT. We included age, gender, presence of GvHD, time
since transplantation, and immunosuppressive treatment
into the model.
Two-tailed p-values of <0.05 were considered significant.
Statistical analyses were performed with STATA® 12.0
(Stata Corp., College Station, TX) and GraphPad Prism
(version 4.0).
Results
Baseline characteristics
The haematological outpatient clinic of the University Hos-
pital Basel, where the questionnaire was distributed, per-
forms around 300 annual check-up visits. During the study
period, 217 questionnaires were returned. Thirty question-
Table 1: General characteristics of the study population (n = 153).
Travelers
(n = 118)
Non-travelers
(n = 35)
p-value
n % n %
Median age (years), IQR 47 37–56 54 39-61 0.3
Males, % 72 61 25 71.4 0.261
Immunosuppressive therapy, % 42 35.6 23 65.7 0.002
Graft-versus-host-disease, % 62 52.5 22 62.9 0.168
Underlying disease
Chronic myeloid leukaemia 21 17.8 4 11.4
Myelodysplastic syndromes / acute myeloblastic leukaemia 36 30.5 12 34.3
Non-Hodgkin lymphoma 50 42.4 16 45.7fe
Hodgkin lymphoma 4 3.4 1 2.9
Congenital immunodeficiency 1 0.8 1 2.9
Aplastic anaemia 6 5.1 1 2.9
IQR = Interquartile range (only for age)
Table 2: Characteristics of 201 journeys performed by 118 patients according to the main destination.
Europe Africa Asia Canada/USA Latin America Total
Number of journeys 138 (100%) 16 (100%) 21 (100%) 19 (100%) 7 (100%) 201 (100%)
Immunosuppressive
therapy
51 (36.7%) 8 (50%) 8 (38.1%) 6 (31.6%) 1 (14.3%)
Graft-versus-host-disease 76 (55.1%) 10 (62.5%) 10 (47.6%) 9 (47.4%) 2 (28.6%)
Median duration, days
(interquartile range)
14 (7‒21) 14 (7‒14) 12 (7‒28) 14 (9‒24) 17 (10‒28)
Counselling before
journey
43 (31.2%) 8 (50 %) 9 (42.9%) 5 (26.3%) 5 (71.4%) 70 (34.8%)
By family doctor 13 (9.4%) 4 (25%) 5 (23.8%) 2 (10.5%) 3 (42.9%) 27 (13.4%)
By haematologist 26 (18.8%) 4 (25 %) 4 (19.0%) 3 (15.8%) 2 (28.6%) 39 (19.4%)
By travel clinic 2 (1.4%) 1 (6.3%) 1 (4.8%) 0 (0%) 1 (14.3%) 5 (2.5%)
Other 10 (7.2%) 1 (6.3%) 3 (14.3%) 0 (0%) 0 (0%) 14 (7.0%)
Symptoms during
journey1
37 (26.8%) 5 (31.3%) 6 (28.6%) 3 (15.8%) 3 (42.9%) 54 (26.9%)
Respiratory 19 (13.8%) 1 (6.3%) 4 (19.0%) 2 (10.5%) 1 (14.3%) 27 (13.4%)
Gastrointestinal 15 (10.9%) 3 (18.8%) 3 (14.3%) 0 (0%) 2 (28.6%) 23 (11.4%)
Fever 4 (2.9%) 0 (0%) 2 (9.5%) 0 (0%) 0 (0%) 6 (3.0%)
Risk during journey2 30 (21.7%) 2 (12.5%) 9 (42.9%) 8 (42.1%) 1 (14.3%) 50 (24.9%)
Food 20 (14.5%) 2 (12.5%) 6 (28.6%) 6 (31.6%) 0 (0%) 34 (16.9%)
Symptoms after journey3 35 (25.4%) 2 (12.5%) 4 (19.0%) 2 (10.5%) 3 (42.9%) 46 (22.9%)
Respiratory 16 (11.6%) 2 (12.5%) 4 (19.0%) 2 (10.5%) 0 (0%) 24 (11.9%)
Gastrointestinal 10 (7.2%) 1 (6.3%) 2 (9.5%) 0 (0%) 0 (0%) 13 (6.5%)
Fever 1 (0.72%) 0 (0%) 2 (9.5%) 0 (0%) 0 (0%) 3 (1.5%)
Intended behaviour before next journey
Counseling4 48 (34.8%) 6 (37.5%) 5 (23.8%) 5 (26.3%) 4 (57.1%) 68 (33.8%)
Inform about local
health care5
51 (37.0%) 4 (25%) 6 (28.6%) 7 (36.8%) 3 (42.9%) 71 (35.3%)
Inform about
vaccination6
65 (47.1%) 9 (56.3%) 11 (52.4%) 8 (42.1%) 5 (71.4%) 98 (48.8%)
Missing data for: 1 20 journeys, 2 39 journeys, 3 37 journeys, 4 54 journeys, 5 58 journeys, 6 47 journeys
Multiple answers possible for 1,2,3,4
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naires were excluded: in 21 cases because of missing
baseline information, 6 patients reported travel duration
shorter than 1 week, 3 refused to fill out the questionnaire,
and 1 patient reported a journey before the transplantation
date. Thus, 187 questionnaires from a total of 153 individu-
als were finally analysed, and 118/153 (77.1%) patients re-
ported travel activity in the previous year. Table 1 summar-
ises the baseline characteristics of the study participants.
The majority of patients (145/153, 94.8%) were in com-
plete remission of their haematological malignancy at the
time of travelling.
Travelling after allo-HSCT
A total of 118/153 (77.1%) reported travel activity, includ-
ing 201 episodes, mostly for vacation (176/201, 87.6%).
Only 15 (7.5%) travel episodes were reported for business
purposes. Forty-two percent of the travellers (50/118) de-
clared multiple trips within 1 year prior to the survey.
The median reported number of travel episodes was 1 (in-
terquartile range [IQR] 1–2). Most travel episodes were
in company (148/201, 73.6%). The accommodation men-
tioned most was hotel (86/201, 42.8%), followed by
privately organised lodging (36/201, 17.9%). European
countries were the most common destinations (138/201,
68.7%), followed by Asia (21/201, 10.5%), North America
(19/201, 9.5%), Africa (16/201, 8.0%) and Latin America
(7/201, 3.5%) (fig. 1). Among European travel destina-
tions, Mediterranean countries dominated (82/201, 40.8%
Italy, Spain, France, Portugal and Greece), followed by
German speaking neighbour countries (19/201, 9.5% Ger-
many and Austria), Nordic countries (14/201 7.0%
Sweden, Norway, Island, Finland, Denmark), Eastern
European countries (11/201, 5.5% Ukraine, Rumania,
Kosovo, Croatia, Hungary, Poland), Western Europe coun-
tries (7/201, 3.5% England, Ireland, Holland) and Canary
Islands (5/201, 2.5%). Table 2 shows the characteristics of
the 201 travel episodes according to destination. There was
a longer median time since transplantation among patients
travelling to non-European compared with European des-
tinations (median 9.3 vs 6.5 years, p = 0.13).
Among all study participants 22.9% (35/153) reported no
travel activity in the previous year. The most common reas-
ons mentioned were “no interest” (12/35, 34.3%), “not
feeling well” (12/35 34.3%), “financial reasons” (4/35,
11.4%), and “recommendation not to travel by the treating
physician” (3/35, 8.6%).
Impact on travel activity
In general, travellers showed a significantly longer time
since transplantation (median 7.5 years, IQR 5–12) com-
pared with non-travellers (median 3 years, IQR 1–5; p
<0.0001). Only 3/201 (1.5%) (France, Israel, Egypt) travel
episodes were within 1 year after transplantation, and 16/
201 (8.0%) – 14/16, 87.5% to European countries – within
2 years post-transplant. Also, patients without immunosup-
pressive treatment were more likely to travel (42/118,
35.6% vs 23/35, 65.7%; p = 0.002). Nevertheless, in the
multivariate analysis, only time after transplantation was
an independent predictor for travel activity after allo-HSCT
(odds ration [OR] 9.056, 95% confidence interval [CI]
2.033–40.337, p = 0.004; table 3). Neither presence of
GvHD nor concurrent immunosuppressive drugs had a sig-
nificant influence on travel activity in the multivariate
model. These two factors also did not prevent patients from
travelling to high-infection-risk continents (table 2).
Pretravel advice and preparation
In only 34.8% (70/201) of travel episodes was pretravel ad-
vice sought. Only in 147 cases a statement regarding in-
tended future travel advice was given. Of those who had
sought pr-travel advice, 94.5% (52/55) would do so again
and among those refusing it, 82.6% (76/92) would do so
in the future. Among the reported travel episodes patients
were more likely to seek pretravel advice when taking
immunosuppressive treatment (49.3% [36/74] vs 26.8%
[34/127], p = 0.001), having a shorter time since allo-
HSCT (median time 4.5 years vs 11 years, p <0.0001)
or GvHD (42.0% [45/107] vs 26.6% [25/94], p = 0.025).
Travel advice was also requested more frequently for travel
to Africa, Asia and Latin America (table 2). A common
source for pretravel information was the haematologist (39/
201, 19.4%), preferably chosen by travellers with a shorter
time since transplantation (3.7 years, IQR = 2.1–5.5),
whereas family doctors were asked at a longer time since
transplantation (5.3 years, IQR = 4.1–8.4).
For only 24/201 (11.9%) travel episodes, patients reported
having received recommendations for vaccination. Also
the patients’ self-reported vaccination status was often
poor. Vaccine status for common vaccines such as tetanus
or influenza could be determined in fewer than half of the
travel episodes. Table 4 summarises the self-reported vac-
cine status in travelling allo-HSCT recipients. For future
travel, 48.8% (98/201) reported that they would inform
themselves about the need of vaccination and 35.3% (71/
201) about local healthcare; 33.8% (68/201) indicated they
would seek advice from a health professional prior to travel
(table 2).
Travel-related illness
Symptoms were reported in 54/201 (26.9%) cases during
travel and in 46/201 (22.9%) after travelling. While travel-
ling, in 27/201 (13.4%) respiratory and in 23/201 (11.4%)
gastrointestinal symptoms were reported, compared with
24/201 (11.9%) and 13/201 (6.5%), respectively, after re-
Table 3: Multivariate regression analysis of possible predictors for travel activity in 153 patients after allogeneic haematopoietic stem cell
transplantation.
Adjusted odds ratio 95% confidence interval p-value
Age, per 10 years older 1.132 0.765–1.675 0.536
Female 1.419 0.43–4.68 0.566
Graft-versus-host-disease 1.105 0.299–4.081 0.881
Immunosuppressive treatment 0.386 0.098–1.513 0.172
Transplantation at least 1 year before journey 9.056 2.033‒40.337 0.004
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turning (table 2). Only six patients reported fever during
travel and three post-travelling. Sixteen out of 201 (8.0%)
patients required medical advice during their travel, and
five of these were hospitalised. Reasons for hospitalisation
were febrile respiratory infection (n = 2), petechial skin
rash (n = 1), dehydration (n = 1) and surveillance after a car
accident (n = 1). In 18/201 (9.0%) travel episodes antibiot-
ics were used, but in only half of these cases had a physi-
cian been contacted.
Within 4 weeks after returning home, 17/201 (8.5%) pa-
tients required medical advice. Among those six patients
were hospitalised, specifically owing to febrile respiratory
infection (n = 2), gastrointestinal infection (n = 2), eye
problems (n = 1), and persistent musculoskeletal pain (n =
1). Three of these six patients had already been hospitalised
at the travel destinations, namely owing to febrile respirat-
ory infection (n = 1), gastrointestinal infection (n = 1), and
persistent musculoskeletal pain (n = 1).
Interestingly, gastrointestinal and respiratory symptoms
were more frequent among travel episodes with pretravel
advice than patients without pretravel advice (p = 0.001
and p = 0.027, respectively). Among travel episodes with
gastrointestinal symptoms during travel (34/201, 16.9%),
in only only five (14.7%) had the patient indicated risky
eating and drinking habits. Risk behaviour was slightly
higher for travelling outside Europe than across Europe and
mostly concerned eating and drinking habits (raw fish or
meat, and ice cubes). There was no clear trend for health
issues during the journey regarding risk behaviour, gender,
time since transplantation, immunosuppressive therapy and
GvHD. Overall, reported risk behaviour was low. The most
frequent risk behaviour while travelling consisted of risky
eating habits (34/201, 16.9%), followed by bathing in stag-
nant water (16/201, 8.0%). Unprotected sex (2/201, 1%)
and blood transfusions (1/201, 0.5%) were rare. Nobody re-
ported receiving tattoos or piercings nor close animal con-
tact.
Discussion
In our study, more than 75% of the allo-HSCT recipients
reported travel activity in the previous year. The time since
allo-HSCT was the most important predictor for travel
activity. Only a minority did not travel, mainly owing to
lack of interest, not feeling well or financial reasons. Most
Table 4: Self-reported vaccination status in 201 travel episodes
among patients after allogeneic haematopoietic stem cell
transplantation.
Vaccination type Self-reported
vaccination status
n %
Tetanus 89 44.3%
Influenza 85 42.3%
Hepatitis B 63 31.3%
Streptococcus pneumoniae 50 24.9%
Poliomyelitis 40 19.9%
Hepatitis A 31 15.4%
Neisseria meningitidis 24 11.9%
Rabies 8 4.0%
Typhoid 4 2.0%
Japanese encephalitis 3 1.5%
patients travelled to European countries. Pretravel advice
was reported by only one-third of allo-HSCT patients.
When travelling in Europe or North America respiratory
health issues dominated, whereas among travellers to the
subtropics and tropics gastrointestinal symptoms were the
most frequent symptoms.
In a Canadian study, solid organ transplant recipients
showed less difference in median time after transplantation
between travelling and non-travelling patients (5 vs 3
years) [20] compared with our study (7 vs 2 years). We
would postulate that allo-HSCT patients waited longer for
travel activities, because of the initial severity of disease
and GvHD with a prolonged immunosuppressed state.
With longer time after allo-SCT, the probability of being
immunocompromised decreases, in contrast to the situation
for solid organ transplant recipients who have a continuous
need for immunosuppressive drugs. In a recent study
among HSCT patients, the incidence of international travel
increased from 13% to 32% between 1 year and 2 years
after transplantation [23]. An American study among pa-
tients after SOT and patients with haematological diseases
showed that travel-related symptoms in immunosuppressed
travellers were mostly minor [1]. In our study, the percent-
ages of reported health issues and the hospitalisation rate
were comparable to a recently published study among trav-
elling patients after HSCT where 7% had a travel-related
illness and 1.8% needed to be hospitalised. In healthy indi-
viduals a similar hospitalisation rate of between 0.5% and
2% has been shown [24–26], fever being the most common
reason, which is in accordance with our study. Allogeneic
HSCT compared with autologous HSCT does not seem to
increase incidence of travel-related illness within the first
2 years. Focusing only on patients after allogeneic HSCT
and including patients with a longer time since transplant-
ation may increase the percentages of chronic GvHD. Cer-
tain reported health issues in our study could be chronic in
nature. In the other study among HSCT recipients, 89% re-
ported having had a good or excellent overall health status
before travel, whereas we did not ask patients about their
wellbeing before departure. Incidence of reported diarrhoe-
al infections was slightly lower than in healthy individu-
als travelling to tropical and subtropical destinations, where
diarrhoea is the most frequent health issue, affecting up to
every third person [23].
In a study among patients with solid tumours, immunosup-
pressive treatment had less impact on travel related-illness
than the infection risk at destination [20]. Nevertheless, it
has to be considered that solid tumour patients typically
have a milder degree and shorter duration of immunosup-
pression compared with those with haematological malig-
nancies.
European studies among healthy individuals focus mostly
on travel to the subtropics and tropics where the prevalence
of pretravel advice is between 50%–65%, which is com-
parable to our study participants who visited tropical coun-
tries. In our study, travel episodes to high-risk countries
had higher percentages of pretravel advice than those to
low-risk countries, which is similar to a recently published
study among HSCT patients. In this study, however, the
number of travellers to low-risk countries seeking medical
advice from a healthcare provider was higher than in our
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study. This finding could be explained by the wider range
of time since transplantation in our study correlating with
the lower probability of seeking pretravel advice. Among
healthy individuals reasons for not seeking pretravel advice
are prior travel experience to a similar country and assumed
level of knowledge [27]. This corresponds with common
reasons for patients after HSCT not seeking pretravel ad-
vice. Additionally, they mentioned no knowledge about
pretravel advice and absence of a recommendation by their
primary care physician or transplant coordinator to seek
pretravel advice. Two-thirds of those HSCT patients not
seeking pretravel advice thought it was unnecessary, a level
that was even higher than in a study among travelling SOT
patients (38%) [3, 23]. In our study, almost all patients with
pretravel advice would contact a physician again, while
those without would not do so in the future. This may un-
derline the maintenance of accustomed travel patterns and
shows the need to identify travelling patients who do not
seek pretravel advice by themselves. Interestingly, it has
been recently shown that patients after HSCT were more
likely to travel internationally soon after HSCT if they
were already used to do so before transplantation. Popu-
lar European travel destinations such as Italy and Greece
might not be considered as high-risk destinations; never-
theless, the current dramatic increase of multidrug-resist-
ant Gram-negative bacteria should not be underestimated
after all when treating immunocompromised hosts. In fact,
travel returners may easily become colonised with
multidrug-resistant bacteria [28].
In our study, patients with a shorter time after allo-HSCT
and with immunosuppressive treatment were more likely to
seek pretravel advice. Although these two factors by them-
selves did not increase the probability for travel-related ill-
ness, in our study patients with pretravel advice were more
often confronted with health issues during their trip. This
phenomenon was also shown in another study among trav-
ellers ill after HSCT. Also in our study, multivariate analys-
is to adjust for other confounders could not be conducted
because of the low number of travel-related health issues.
It might be that patients with a higher susceptibility for
health issues were more likely to seek pretravel advice. We
did not ask about their wellbeing prior to their travel epis-
ode. It is notable that even half of travellers under immun-
osuppressive treatment did not contact a health profession-
al prior to travel. This is in line with other studies among
immunosuppressed travellers [2, 3]. HSCT patients con-
tacted their haematologist for pretravel advice by far the
most often, corresponding to another study among HSCT
patients [23]. We did not ask whether Internet sources (such
as www.safetravel.ch) were contacted. However, specific
information on the Internet about allo-HSCT and travel is
rare. This may underline the need of personal advice by a
health professional prior to travel. Another challenge is that
pretravel advice is often sought only within 4 weeks before
departure by both immunosuppressed and healthy individu-
als [1, 27]. Within this time period it might not be possible
to reach sufficient vaccine-induced immunity and properly
prepare for the trip e.g. localization of emergency rooms.
Even if patients after HSCT received reminder telephone
calls and vaccination cards based on the updated vaccin-
ation guidelines, one-third missed at least one vaccination
set within 14 months post-transplant [29]. Therefore, it is
recommendable to check patients’ vaccination status regu-
larly and to direct their attention to the need of a repeated
immunisation after allo-HSCT.
It might be that to the majority in our study no vaccination
was recommended because their protection was already
sufficient. Nevertheless, a recently published study among
hematopoietic cell transplant physicians showed a large
gap between the post-HCT guidelines and clinical practice.
Only 38% of patients received the first series of vaccina-
tions within the recommended 6 months after HSCT [30].
The most common reasons to withhold or delay vaccines
were current use of steroids (70%) and GvHD (87%).
Therefore, patients undergoing allo-HCT had an increased
risk for being unvaccinated. Based on International
Guidelines from 2009 the Official Swiss vaccination re-
commendations for HSCT patients propose vaccinating re-
gardless of GvHD (acute or chronic) with nonlive vaccines
6 months after stem cell transplantation [31, 32].
In our study fewer than half of the patients could report
on their own vaccination status in spite of a generally pos-
itive attitude towards vaccination. This is comparable to
healthy individuals showed in a study among European
travellers, where over one half could not report their pro-
tection against hepatitis A or B [33].
This study has some limitations as a result of its retrospect-
ive nature and, therefore, considerable recall bias. Under-
and over-reporting of symptoms is possible. Nevertheless,
we can assume that severe illness and hospitalisation would
be remembered and indicated in the questionnaire. It might
be that patients with positive travel experiences were more
willing to complete the questionnaire than people with less
good holiday memories or no travel activity. As we have
not performed an analysis of the people not responding
to the questionnaire, we cannot rule out a responder bias.
As not much detail on the aetiology of reported diseases
could be acquired, a clear association between symptoms
and travel is difficult. In addition, this study is from a single
centre in Switzerland and, therefore, some results might not
be directly transferrable to other centres.
Comparisons between studies among other immunocom-
promised travellers are difficult, as existing studies focus
on travellers from North America, who may prefer other
travel destinations closer to their home country. Also
among healthy individuals travel related issues are more
frequently investigated for countries outside of Europe.
Furthermore, the study represents data only from a single
institution in Switzerland, where the composition of the
population may differ from other transplant centres. For ex-
ample, travellers visiting their families and friends might
be under-represented compared with other countries with
more immigration history. This possibility has to be con-
sidered, as studies showed that this group of patients is es-
pecially susceptible for travel-related diseases because they
are less cautious about risk behaviour [34]. We did not ask
about the origin of the patients and therefore also did not
perform an analysis of visiting friends and relatives as a
risk factor.
One important strength of this study is the remarkable num-
ber of travel episodes among allo-HSCT patients travel-
ling in Europe; however, certain subgroups, such as travel-
Original article Swiss Med Wkly. 2015;145:w14136
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related illnesses, were still rare, so that no clear analysis
could be performed.
We conclude that patients after allo-HSCT show unexpec-
tedly high travel activity, increasing further with longer
time after transplantation. All patients should be encour-
aged to contact their haematologist prior to travel, as they
are most familiar with the complex medical condition of
patients after allo-HSCT. On the other hand, haematolo-
gists should ask patients regularly about intended travel
plans during their annual health visits. Prevention measures
such as vaccination should be discussed early enough
between patients and their haematologist. Travelling after
allo-HSCT can be considered safe, but nevertheless pre-
travel advice is crucial. It would be worth striving for
further prospective investigations about travel activity in
wider populations among patients after allo-HSCT to im-
prove their travel safety and therefore quality of life.
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Figures (large format)
Figure 1
Distribution of reported travel destinations. In total 201 travel episodes were reported.
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